Compare IXHL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | ICCC |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | IXHL | ICCC |
|---|---|---|
| Price | $0.45 | $5.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.6M | 20.4K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $12,000.00 | ★ $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.85 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $0.08 | $4.28 |
| 52 Week High | $2.25 | $7.60 |
| Indicator | IXHL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 55.08 |
| Support Level | $0.35 | $4.72 |
| Resistance Level | $0.50 | $5.36 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 80.58 | 100.00 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.